Pharmakologische Hinweise zur Anwendung von Ganoderma lucidum bei Tumorerkrankungen

Zusammenfassung

In der chinesischen Medizin ist der Einsatz des Pilzes Ganoderma lucidum zur Gesundheitsförderung, aber auch bei Indikationen wie z.B. Krebserkrankungen seit langem dokumentiert. Pharmakologische Untersuchungen deuten darauf hin, dass bestimmte Inhaltsstoffe antitumoröse und immunstimulierende Wirkungen haben können. Tummorhemmende Effekte wurden sowohl in vitro als auch im Tierversuch nachgewiesen. Es fehlen aber klinische Studien, die den Einsatz des Pilzes in der Krebsbehandlung begründen würden.

Summary

Pharmaceutical application and anti-tumour activity of Ganoderma lucidum.

In Chinese Medicine, the usage of the mushroom Ganoderma lucidum is well documented, particularly to maintain and improve health, but also to treat patients with cancer. Several pharmaceutical studies were performed to verify the efficacy of distinct compounds from Ganoderma lucidum. Tumour-inhibiting effects were reported in vitro and in animal experiments. Nevertheless, only a few clinical studies have been undertaken to prove its efficacy in the treatment of tumour patients. The available data pool offers at least some hints about the possible utility of Ganoderma and thus a basis for promoting the mushroom's pharmaceutically effective extracts to the status of supplements in general health maintenance. To verify beneficial effects of Ganoderma lucidum in the treatment of tumour patients, well planed clinical studies are still necessary.

Schlüsselwörter

Ganoderma lucidum - Immunmodulation - Zytotoxizität - klinische Studien - Tumorpatienten

Keywords

Ganoderma lucidum - immunomodulation - cytotoxicity - clinical studies - tumour patients

Literatur

• 01 Boh B, Berovic M, Zhang J, Zhi-Bin L. Ganoderma lucidum and its pharmaceutically active compounds.  Biotechnol Annu Rev. 2007;  13 265-301
• 02 Chan W K, Lam D T, Law H K, Wong W T, Koo M W, Lau A S. et al . Ganoderma lucidum mycelium and spore extracts as natural adjuvants for immunotherapy.  J Altern Complement Med. 2005;  11 (6) 1047-1057
• 03 Chan W K, Law H K, Lin Z B, Lau Y L, Chan G C. Response of human dendritic cells to different immunomodulatory polysaccharides derived from mushroom and barley.  Int Immunol. 2007;  19 (7) 891-899
• 04 Chen X, Hu Z P, Yang X X, Huang M, Gao Y, Tang W. et al . Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer.  Int Immunopharmacol. 2006;  6 (3) 499-508
• 05 Cheng K C, Huang H C, Chen J H, Hsu J W, Cheng H C, Ou C H. et al . Ganoderma lucidum polysaccharides in human monocytic leukemia cells: from gene expression to network construction.  BMC Genomics. 2007;  8 411
• 06 Gao Y, Gao H, Chan E, Tang W, Xu A, Yang H. et al . Antitumor activity and underlying mechanisms of ganopoly, the refined polysaccharides extracted from Ganoderma lucidum, in mice.  Immunol Invest. 2005;  34 (2) 171-198
• 07 Gao Y, Tang W, Dai X, Gao H, Chen G, Ye J. et al . Effects of water-soluble Ganoderma lucidum polysaccharides on the immune functions of patients with advanced lung cancer.  J Med Food. 2005;  8 (2) 159-168
• 08 Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients.  Immunol Invest. 2003;  32 (3) 201-215
• 09 Ji Z, Tang Q, Zhang J, Yang Y, Jia W, Pan Y. Immunomodulation of RAW264.7 macrophages by GLIS, a proteopolysaccharide from Ganoderma lucidum.  J Ethnopharmacol. 2007;  112 (3) 445-450
• 10 Jiang J, Grieb B, Thyagarajan A, Sliva D. Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-kappaB signaling.  Int J Mol Med. 2008;  21 (5) 577-584
• 11 Jiang J, Slivova V, Harvey K, Valachovicova T, Sliva D. Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/NF-kappaB signaling.  Nutr Cancer. 2004;  49 (2) 209-216
• 12 Jiang J, Slivova V, Sliva D. Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling.  Int J Oncol. 2006;  29 (3) 695-703
• 13 Kashimoto N, Hayama M, Kamiya K, Watanabe H. Inhibitory effect of a water-soluble extract from the culture medium of Ganoderma lucidum (Rei-shi) mycelia on the development of pulmonary adenocarcinoma induced by N-nitrosobis (2-hydroxypropyl) amine in Wistar rats.  Oncol Rep. 2006;  16 (6) 1181-1187
• 14 Kim K C, Kim J S, Son J K, Kim I G. Enhanced induction of mitochondrial damage and apoptosis in human leukemia HL-60 cells by the Ganoderma lucidum and Duchesnea chrysantha extracts.  Cancer Lett. 2007;  246 (1–2) 210-217
• 15 Kwok Y, Ng K F, Li C C, Lam C C, Man R Y. A prospective, randomized, double-blind, placebo-controlled study of the platelet and global hemostatic effects of Ganoderma lucidum (Ling-Zhi) in healthy volunteers.  Anesth Analg. 2005;  101 (2) 423-6
• 16 Lin Z B. Cellular and molecular mechanisms of immuno-modulation by Ganoderma lucidum.  J Pharmacol Sci. 2005;  99 (2) 144-153
• 17 Liu J, Shimizu K, Konishi F, Kumamoto S, Kondo R. The anti-androgen effect of ganoderol B isolated from the fruiting body of Ganoderma lucidum.  Bioorg Med Chem. 2007;  15 (14) 4966-4972
• 18 Muller C I, Kumagai T, O'Kelly J, Seeram N P, Heber D, Koeffler H P. Ganoderma lucidum causes apoptosis in leukemia, lymphoma and multiple myeloma cells.  Leuk Res. 2006;  30 (7) 841-848
• 19 Nonaka Y, Shibata H, Nakai M, Kurihara H, Ishibashi H, Kiso Y. et al . Anti-tumor activities of the antlered form of Ganoderma lucidum in allogeneic and syngeneic tumor-bearing mice.  Biosci Biotechnol Biochem. 2006;  70 (9) 2028-2034
• 20 Pang X, Chen Z, Gao X, Liu W, Slavin M, Yao W. et al . Potential of a novel polysaccharide preparation (GLPP) from Anhui-grown Ganoderma lucidum in tumor treatment and immunostimulation.  J Food Sci. 2007;  72 (6) 435-S442
• 21 Paterson R R. Ganoderma – a therapeutic fungal biofactory.  Phytochemistry. 2006;  67 (18) 1985-2001
• 22 Sliva D. Cellular and physiological effects of Ganoderma lucidum (Reishi).  Mini Rev Med Chem. 2004;  4 (8) 873-879
• 23 Sliva D. Ganoderma lucidum (Reishi) in cancer treatment.  Integr Cancer Ther. 2003;  2 (4) 358-364
• 24 Stanley G, Harvey K, Slivova V, Jiang J, Sliva D. Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-beta1 from prostate cancer cells.  Biochem Biophys Res Commun. 2005;  330. (1) 46-52
• 25 Thyagarajan A, Zhu J, Sliva D. Combined effect of green tea and Ganoderma lucidum on invasive behavior of breast cancer cells.  Int J Oncol. 2007;  30 (4) 963-969
• 26 Wachtel-Galor S, Tomlinson B, Benzie I F. Ganoderma lucidum („Lingzhi”), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study.  Br J Nutr. 2004;  91 (2) 263-269
• 27 Wang G, Zhao J, Liu J, Huang Y, Zhong J J, Tang W. Enhancement of IL-2 and IFN-gamma expression and NK cells activity involved in the anti-tumor effect of ganoderic acid Me in vivo.  Int Immunopharmacol. 2007;  7 (6) 864-870
• 28 Weng C J, Chau C F, Hsieh Y S, Yang S F, Yen G C. Lucidenic acid inhibits PMA-induced invasion of human hepatoma cells through inactivating MAPK/ERK signal transduction pathway and reducing binding activities of NF-kappaB and AP-1.  Carcinogenesis. 2008;  29 (1) 147-156
• 29 Xie J T, Wang C Z, Wicks S, Yin J J, Kong J, Li J. et al . Ganoderma lucidum extract inhibits proliferation of SW 480 human colorectal cancer cells.  Exp Oncol. 2006;  28 (1) 25-29
• 30 Yang Q Y, Wang M M. The effect of ganoderma lucidum extract against fatigue and endurance in the absence of oxygen. In: Buchanan PK, Hseu RS, Moncalvo JM, editors. 5th Intl. Mycol. Congr., Proc.Contributed.Symposium. 59A,B Taipe; 1995: 101-113
• 31 Yao P Y, Gao Z M, Fang S T, Ke L. Evaluation of the subsidiary effects of taking PSP orally on the chemotherapy of stomach cancer. In: Yang QY, Kwok CY, editors. 1993 PSP Intl. Symposium Shanghai; Fudan U. Press 1993: 269-270
• 32 Yue Q X, Cao Z W, Guan S H, Liu X H, Tao L, Wu W Y. et al . Proteomic characterization of the cytotoxic mechanism of ganoderic acid D and computer automated estimation of the possible drug-target network.  Mol Cell Proteomics. 2007; 
• 33 Yue G G, Fung K P, Tse G M, Leung P C, Lau C B. Comparative studies of various ganoderma species and their different parts with regard to their antitumor and immunomodulating activities in vitro.  J Altern Complement Med. 2006;  12 (8) 777-789
• 34 Yue Q X, Xie F B, Guan S H, Ma c, Yang M, Jiang B H. et al . Interaction of Ganoderma triterpenes with doxorubicin and proteomic characterization of the possible molecular targets of Ganoderma triterpenes.  Cancer Sci. 2008; 
• 35 Zaidman B Z, Wasser S P. Androgen receptor-dependent and -independent mechanisms mediate Ganoderma lucidum activities in LNCaP prostate cancer cells.  Int J Oncol. 2007;  31 (4) 959-967
• 36 Zaidman B Z, Wasser S P. Coprinus comatus and Ganoderma lucidum interfere with androgen receptor function in LNCaP prostate cancer cells.  Mol Biol Rep. 2007; 
• 37 Zhou X, Lin J, Yin Y, Zhao J, Sun X, Tang K. Ganodermataceae: natural products and their related pharmacological functions.  Am J Chin Med. 2007;  35 (4) 559-574
• 38 Zhu X L, Chen A F, Lin Z B. Ganoderma lucidum polysaccharides enhance the function of immunological effector cells in immunosuppressed mice.  J Ethnopharmacol. 2007;  111 (2) 219-226

Korrespondenzadresse